LRP4 (LDL Receptor Related Protein 4)

This study highlights the importance of considering alternative diagnoses in patients with dSnMG and emphasizes the value of comprehensive testing. Early recognition of causative etiologies can significantly improve patient management and outcome and prevent unnecessary exposure to prolonged immunosuppression.

P1, N=18, Recruiting, Beijing Boren Hospital | Not yet recruiting --> Recruiting

P1, N=18, Not yet recruiting, Beijing Boren Hospital

P1/2, N=12, Active, not recruiting, Cabaletta Bio | Recruiting --> Active, not recruiting

P1, N=0, Withdrawn, Nanjing Bioheng Biotech Co., Ltd. | N=18 --> 0 | Not yet recruiting --> Withdrawn

The TLR4-NLRP4 axis is a context-dependent regulator of gut and systemic immunity. Targeted modulation of this pathway represents a promising strategy to restore immune homeostasis while preserving host defense, supporting its relevance as a translational therapeutic target across multiple immune-mediated disorders.

This study confirmed the validity of the cyclophosphamide-busulfan induced mouse model of ovarian senescence, highlighted both the shared and distinct molecular mechanisms of physiological and pathological ovarian aging, and identified promising early biomarkers and therapeutic intervention targets.

P1, N=36, Not yet recruiting, Dongguan Taixin Hospital; Dongguan Taixin Hospital

All three aforementioned genes may be associated with the responsiveness of malignant human B-cell Lines to R-CHOP therapeutic agents. These results demonstrated that 19-GPS signature was effective and might potentially assist in guiding the prognosis and treatment options for DLBCL.

The evolving landscape of gMG treatment reflects a shift toward immunopathology-based precision medicine. Better characterization of subtype-specific molecular signatures and immune dysfunctions is essential to guide clinical decision-making and improve outcomes for treatment-refractory patients.

We further demonstrate that overexpression of LRP4 is common in residual disease post-treatment and is associated with breast tumors of poor prognosis. This work has demonstrated that the LRP4/YAP axis drives radioresistance by promoting the emergence of RTP cells through radiation-induced plasticity, and that modulation of the LRP4/YAP axis is a promising strategy for sensitizing breast cancers to radiotherapy, opening up a new avenue for improving patient outcomes.

We review the evolution of diagnostic assays, from early RIA to modern CBA, and addresses interpretative pitfalls, particularly in borderline or "seronegative" cases. Finally, the authors address the significance of accurate autoantibody detection in the diagnosis and management of patients with one of the antibody MG subtypes, as well as in patients with other autoimmune conditions and thymic malignancies.